1-5 of 5
Rui Zhang, MSc
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

CAR2.0 Therapy for the Management of Post-Transplantation Relapse of B-Cell Acute Lymphoblastic Leukemia

Rui Zhang, MSc, Juan Xiao, MD PhD, Zhouyang Liu, MSc, Yuan Sun, MD, Sanfang Tu, MD& PhD, Yuhua Li, MD& PhD, Leping Zhang, MD PhD, Yifei Cheng, MD PhD, Song Xue, MSc, Yongping Zhang, MD PhD, Kai Wang, MD PhD, Bin Wang, MD MSc, Huyong Zheng, MD PhD, Nobuhiro Nishio, MD PhD, Yoshiyuki Takahashi, MD PhD, Jia Feng, MD PhD, Haichan Xu, MD PhD, Yuchen Liu, MSc, Yuchen Li, MSc, Cheng Jiao, MD PhD, Biljana N. Horn, MD, Lung-Ji Chang, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 7.
https://doi.org/10.1182/blood-2020-141531
Published: 2020
Journal Articles

Improved Safety and Efficacy of a Multi-Target Chimeric Antigen Receptor Modified T Cell Therapy (4SCAR2.0) Against Relapsed or Refractory Lymphomas

Rui Zhang, MSc, Yuhua Li, MD& PhD, Sanfang Tu, MD& PhD, Rui Huang, MD& PhD, Xun Lai, MD, Leping Zhang, MD PhD, Eugene E. Zvonkov, MD PhD, Valeriy G. Savchenko, MD PhD, Nelly G Gabeeva, PhD, Yuchen Liu, MSc, Yuchen Li, MSc, Cheng Jiao, MD PhD, Lan Deng, MD PhD, Xuan Zhou, MD, Hongyu Zhang, MD PhD, Wenli Zhang, MD, Lung-Ji Chang, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 47.
https://doi.org/10.1182/blood-2020-141515
Published: 2020
Journal Articles

Phase I/II Trial of Multi-Target Chimeric Antigen Receptor Modified T Cells (4SCAR2.0) Against Relapsed or Refractory Lymphomas

Lung-Ji Chang, PhD, Yuhua Li, MD& PhD, Sanfang Tu, MD& PhD, Xun Lai, MD, Rui Huang, MD& PhD, Shih-Ting Tsao, MSc, Yu-Chen Liu, MSc, Rui Zhang, MSc, Lan Deng, MDPhD, Xuan Zhou, MD, Hongyu Zhang, PhD MD, Wenli Zhang, MD, Yuchen Li, MSc
Journal: Blood
Blood (2018) 132 (Supplement 1): 225.
https://doi.org/10.1182/blood-2018-99-114396
Published: 2018
Journal Articles

Chimeric Antigen Receptor 4SCAR-GD2-Modified T Cells Targeting High-Risk and Recurrent Neuroblastoma: A Phase II Multi-Center Trial in China

Lihua Yang, MDPhD, Xiaoli Ma, MDPhD, Yu-Chen Liu, MSc, Wen Zhao, MDPhD, Lihua Yu, PhD, Maoquan Qin, MDPhD, Guanghua Zhu, MDPhD, Kai Wang, MDPhD, Xiaodong Shi, MD, Zhaoxia Zhang, MD, Jingfu Wang, MD, Yuan Sun, MD, Lujia Dong, MD, Shih-Ting Tsao, MSc, Rui Zhang, MSc, Lung-Ji Chang, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3335.
https://doi.org/10.1182/blood.V130.Suppl_1.3335.3335
Published: 2017
Journal Articles

Double CD19/CD22 Chimeric Antigen Receptor-Modified T Cells for the Treatment of Stage IV Relapsed and Refractory Follicular Lymphoma

Xun Lai, MD, Xuezhong Gu, MD, Shih-Ting Tsao, MSc, Qin Zhang, PhD, Yu-Chen Liu, MSc, Jiang Yaxian, PhD, Li Yan, MD, Jun Chun, MD, Rui Zhang, MSc, Yunyun Du, MD, Xiaoli Gao, MD, Yingyu Yang, Xiaolian Qiu, Mingjing Fang, MA, Song Wei, PhD, Lung-Ji Chang, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 5154.
https://doi.org/10.1182/blood.V130.Suppl_1.5154.5154
Published: 2017